Background: From the viewpoint of health and education, traumatized children and adolescents who have fled from war and conflict zones to Switzerland represent a high-risk group, as they suffer from psychiatric symptoms to an above-average extent and on several levels: somatic, psychological, psychosomatic, and psychosocial.

Objectives: The complexity and severity of these problems overwhelm the existing school structures in many cases: There is a clear need for psychotherapeutic interventions here that goes beyond purely verbal conversational therapy and provides an holistic concept.

Methods: We propose the following novel approach: "Trauma group therapy with karate-do for war-traumatized children and adolescents" which integrates and applies the evidence-based methods of integrative Budo-Therapy, trauma-focused Cognitive Behavioral Therapy (TF-CBT), Narrative Exposure Therapy (NET) and Integrative Gestalt Therapy according to Dr. Hilarion Petzold (EAG-FPI) and validated it in a group of approximately 12 children from war and conflict zones who attend the public schools of the city of Zürich.

Results: Qualitative feedback received from the teachers is promising. They report that it is now better possible for the children who go to ouer "Trauma group therapy with karate-do for war-traumatized children and adolescents" to concentrate at school and also to better regulate their feelings.

Conclusion: Ouer approach seems to be a promising intervention for traumatized children and adolecents. Though it needs further evaluation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523532PMC
http://dx.doi.org/10.3389/fpsyg.2024.1301671DOI Listing

Publication Analysis

Top Keywords

group therapy
12
therapy karate-do
12
karate-do war-traumatized
12
war-traumatized children
12
children adolescents
8
traumatized children
8
war conflict
8
conflict zones
8
"trauma group
8
children adolescents"
8

Similar Publications

The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare rituximab (R) alone versus R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL). Patients with grade 1-3a FL, requiring systemic therapy, were randomized to either R (n=77; 375 mg/m2 IV x 1, weeks 1-4) or RL (n=77; R on the same schedule and L at 15 mg daily continuously). Responders (evaluated at 10 weeks) repeated R during weeks 12-15 with or without L (for a total of 18 weeks).

View Article and Find Full Text PDF

In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic review and meta-analysis of 62 studies, encompassing 3,487 patients from the years 1960 to 2022. Our findings reveal that patients with up to 10% clonal plasma cells in their bone marrow (BM), denoted as plasmacytoma +, had a significantly reduced median disease-free survival (DFS) of 15.7 months vs.

View Article and Find Full Text PDF

MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial.

Blood

January 2025

Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hos, Cologne, Germany.

The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were enrolled and two patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of one prior therapy (range 1-5), 18 patients (45%) had already received a BTK inhibitor (BTKi), seven patients (17.

View Article and Find Full Text PDF

Background: Barriers to mental health assessment and intervention have been well documented within South Africa, in both urban and rural settings. Internationally, evidence has emerged for the effectiveness of technology and, specifically, app-based mental health tools and interventions to help overcome some of these barriers. However, research on digital interventions specific to the South African context and mental health is limited.

View Article and Find Full Text PDF

Background And Objectives: Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term efficacy and safety profile of the high-efficacy DMT ocrelizumab (OCR) as first-line therapy for early-stage relapsing MS (RMS).

Methods: Post hoc exploratory analyses of efficacy and safety were performed in a subgroup of treatment-naive patients with RMS who received ≥1 dose of OCR in the multicenter OPERA I/II (NCT01247324/NCT01412333) studies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!